1,091 active patients at Dec. 31, 2016, an increase of 80 percent versus Dec. 31, 2015
ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR), a commercial-stage oncology company developing a proprietary therapy for solid tumors, will provide a business update as well as its preliminary operating statistics for the fourth quarter and full year 2016 at the 35th Annual J.P. Morgan Healthcare Conference on Jan. 11, 2017 in San Francisco.
“The fourth quarter of 2016 was the eighth consecutive quarter of active patient growth for Novocure since the presentation of our successful EF-14 phase 3 pivotal trial data in newly diagnosed glioblastoma (GBM),” said Asaf Danziger, Novocure’s Chief Executive Officer. “As of Dec. 31, 2016, we had nearly 1,100 active patients on treatment, including 256 patients in EMEA, reflecting the increasing importance of our non-U.S. markets.”
Mr. Danziger continued, “The fourth quarter of 2016 was also marked by significant clinical milestones. A long-term analysis of the EF-14 data, presented at the 21st Annual Scientific Meeting of the Society for Neuro-Oncology in November, demonstrated a 70 percent improvement in survival rate at four years for patients treated with Optune together with temozolomide compared to patients treated with temozolomide alone. During our R&D day, we also shared topline results from phase 2 pilot studies in advanced pancreatic cancer, recurrent ovarian cancer and mesothelioma, suggesting that Tumor Treating Fields, when added to standard of care treatments, may improve patient outcomes.” *
Fourth Quarter and Full Year 2016 Operating Statistics
- There were 1,091 active patients on Optune therapy on Dec. 31, 2016, an increase of 80 percent versus Dec. 31, 2015. Of the active patients, 835 were in the U.S. and 256 were in Novocure’s EMEA markets.
- 706 prescriptions were received in the fourth quarter of 2016, an increase of 27 percent versus the fourth quarter of 2015. 544 of the prescriptions were received in the U.S. and 162 were received outside of the U.S., primarily in Europe.
- 2,808 prescriptions were received in 2016, an increase of 58 percent versus 2015. Of the prescriptions, 2,344 were received in the U.S. and 464 were received outside of the U.S., primarily in Europe.
* TTFields are not approved for the treatment of pancreatic cancer, recurrent ovarian cancer or mesothelioma. Their safety and effectiveness in these indications has not been established.
Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on March 1, 2016, with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.
Media and Investor Contact
Ashley Cordova, 212-767-7558